Nasdaq IPOs

Updated Monday, 7/20. Following a flurry of launches on Monday (and one postponement, ACell), seven IPOs and at least two SPACs plan to raise over $5.0 billion in the week ahead, led by Jamf Holding (JAMF). The IPO market is on a hot streak, and the IPO pipeline is filling u

Updated Monday, 7/20. Following a flurry of launches on Monday (and one postponement, ACell), seven IPOs and at least two SPACs plan to raise over $5.0 billion in the week ahead, led by Jamf Holding (JAMF). The IPO market is on a hot streak, and the IPO pipeline is filling u

Four IPOs and one SPAC plan to raise $663 million in the week ahead, led by Jamf Holding (JAMF). The IPO market is on a hot streak, and the IPO pipeline is filling up as filing activity remains high. Several companies could join the IPO calendar in the coming week, including lead

Eight IPOs and six SPACs entered public markets this past week, led by nCino (NCNO), which soared 195% in the biggest first-day pop for a US tech company in nearly 20 years. Cloud banking software provider nCino (NCNO) upsized and priced above the upwardly revised range to raise

Eight IPOs and six SPACs entered public markets this past week, led by nCino (NCNO), which soared 195% in the biggest first-day pop for a US tech company in nearly 20 years. Cloud banking software provider nCino (NCNO) upsized and priced above the upwardly revised range to raise

Yucaipa Acquisition, a blank check company formed by private equity firm The Yucaipa Companies, filed on Friday with the SEC to raise up to $300 million in an initial public offering. The Los Angeles, CA-based company plans to raise $300 million by offering 30 million units at $1

Processa Pharmaceuticals, which is developing an analog therapy for necrotic skin disease, announced terms for its IPO on Friday. The Hanover, MD-based company plans to raise $20 million by offering 2.5 million shares at a price range of $7 to $9. At the midpoint of the proposed

BowX Acquisition, a blank check company formed by Bow Capital Management to acquire a TMT business, filed on Friday with the SEC to raise up to $350 million in an initial public offering. The Menlo Park, CA-based company plans to raise $350 million by offering 35 million units at

Freeline Therapeutics, a Phase 1/2 biotech developing gene therapies for rare diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The company's lead candidate, FLT180a, an investigational gene therapy medicinal product candidate for t

Checkmate Pharmaceuticals, a clinical stage immuno-oncology biotech developing therapies for solid tumors, filed on Friday with the SEC to raise up to $75 million in an initial public offering. The company's sole candidate, CMP-001, is a differentiated Toll-like re

Holicity, a blank check company focused on acquiring a TMT business, filed on Friday with the SEC to raise up to $250 million in an initial public offering. The Kirkland, WA-based company plans to raise $250 million by offering 25 million units at a price of $10. Each unit consis

Health Sciences Acquisitions 2, the second blank check company formed by RTW Investments to acquire a biopharma or medtech business, filed on Friday with the SEC to raise up to $125 million in an initial public offering. The New York, NY-based company plans to raise $125 million

NetSTREIT, a diversified retail REIT focused on the central United States, filed on Friday with the SEC to raise up to $100 million in an initial public offering. NetSTREIT's portfolio includes 163 single-tenant retail net leased properties spanning 34 states and its tenants incl

Renalytix AI, which is commercializing AI-powered diagnostic tests for kidney disease, raised $74 million by offering 5.5 million ADS equivalents at $13.50, below the as-converted last close of its shares on London's AIM board (RENX). At pricing, the company commands a fully dilu

Deerfield Healthcare Technology Acquisitions, the third healthcare-focused blank check company formed by Deerfield Management and Robert Barasch, raised $125 million by offering 12.5 million units at $10. Each unit consists of one share of common stock and one-fifth of a warrant,

ALX Oncology, a Phase 1 immuno-oncology biotech developing CD47 checkpoint inhibitors, raised $162 million by offering 8.5 million shares at $19, above the range of $15 to $17. The company offered 0.5 million more shares than anticipated. At pricing, the company commands a fully

Berkeley Lights, which provides a single cell manipulation platform for drug discovery and development, raised $178 million by offering 8.1 million shares at $22, above the upwardly revised range of $19 to $20. The company offered 0.7 million more shares than anticipated. It orig

Pandion Therapeutics, a Phase 1 biotech developing engineered T cells for autoimmune diseases, raised $135 million by offering a further upsized 7.5 million shares at $18, the high end of the $16 to $18 range. The company originally filed to offer 5.5 million shares, before incre

Fathom Holdings, a cloud-based full-service real estate brokerage, announced terms for its IPO on Thursday. The Cary, NC-based company plans to raise $20 million by offering 2.5 million shares (8% insider) at a price range of $7 to $9. At the midpoint of the proposed range, Fatho

1847 Goedeker, which operates an e-commerce platform for appliances and home goods, lowered the proposed deal size for its upcoming IPO on Thursday. The Ballwin, MO-based company now plans to raise $10 million by offering 1 million shares at a price range of $9 to $11. The compan